# Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

> **NCT05588609** · PHASE2 · TERMINATED · sponsor: **Partner Therapeutics, Inc.** · enrollment: 13 (actual)

## Conditions studied

- NSCLC Harboring NRG1 Fusion
- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Afatinib Oral Tablet
- **DRUG:** Enzalutamide Pill
- **DRUG:** Abiraterone acetate tablets
- **BIOLOGICAL:** MCLA-128

## Key facts

- **NCT ID:** NCT05588609
- **Lead sponsor:** Partner Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-17
- **Primary completion:** 2025-07-03
- **Final completion:** 2025-07-03
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Merus terminated the study early due to changes in organizational priorities.
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05588609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05588609, "Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05588609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*